Arena Pharmaceuticals vs. Vivus: Which Is a Better Weight Loss Drug for Investors?

Arena Pharmaceuticals (NASDAQ:ARNA) and Vivus (NASDAQ:VVUS) are battling in the minds of investors as each promises a drug with the potential to cause weight loss- a sure moneymaker in a country in which many people are unhappy with their weight. Vivus’s drug, Qsymia (also known as Qnexa), was approved by the FDA earlier this month. Arena’s Belviq has also been approved, though it should come to market later than Qsymia if both drugs are released on schedule. At a basic level, the contest between the two drugs is between efficiency and safety concerns, while the contest between the two companies involves the marketability of their drugs and their ability to profit.

While Qsymia is somewhat more effective than Belviq, according to study data, the gap is not particularly large: Belviq trial subjects lost 3-4% of their body weight in one year, and some subjects saw much larger losses, compared to Qsymia’s average of 10% of body weight lost in the highest tested dose. In addition, one of Qsymia’s active ingredients has been shown to increase the risk of birth defects; again, the safety gap might not be particularly large in Belviq’s favor, with Arena attempting to rule out potential cancer and heart health risks from the drug. However, given these differences, even if patients might tend to prefer Qsymia physicians might encourage them to take Belviq, at least at first. Doctors might also spin the information provided in order to encourage their patients to go with Arena’s drug and therefore reduce the risk of complications and expensive legal disputes.

John Burbank PASSPORT CAPITAL

Clearly the strengths and weaknesses of the two drugs convert to advantages and disadvantages of each company relative to the other, but each has an additional drawback. Arena has an agreement to only receive a minority of the revenue from Belviq sales in the US, with the remainder going to a partner who will market the drug and also cover much of the costs of additional clinical trials; Vivus has no such agreement. Vivus’s problem is less certain, but potentially more damaging. Citron Research, a group which publishes investigations of stocks which it believes have had their prospects tremendously overvalued by the Street, turned its sights on the company earlier this month. The stock has fallen about 13% since Citron claimed that one of the compounds used in Qsymia is under patent protection for weight loss treatment and that the drug is a combination of two widely available generics, among other accusations. Unless investors have the legal background to analyze and reject these claims, or are willing to take substantial financial risk, they may want to avoid the stock. Citron and many critics of Vivus also discuss insider selling activity at the company (see a history of insider selling at Vivus).

Between the two, hedge funds have generally bet on Vivus despite the dispute over the companies’ product offerings. According to 13F filings, Daniel Gold’s QVT Financial owned 8.2 million shares of VVUS at the end of March 2012. This made it the largest holding in his 13F portfolio, and made QVT the largest hedge fund holder of the stock. QVT is also the largest hedge fund holder of ARNA, according to the same filings, but only owned 3.3 million shares; taking the two stocks’ prices into account, QVT’s position in VVUS was 18 times larger (see the rest of QVT’s portfolio). Passport Capital, managed by John Burbank, increased its holdings of VVUS in the first three months of 2012 to 7.4 million shares (find other stock picks from Passport Capital).

We think that the intellectual property issues and insider selling at Vivus are causes for concern, and our guess is that, barring any unforeseen developments, doctors will tend to recommend the somewhat safer Belviq to their patients, with Qsymia being a “plan B” in the event the first drug is not effective enough. This is particularly true for patients who are seeking to lose weight for cosmetic rather than purely medical reasons, a large segment of the market for a weight loss drug.  While Arena would not fully benefit from Belviq’s market opportunity, the stock may be a better buy than Vivus.

This article was updated to include information about Arena’s marketing agreement for Belviq.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

Top 6 Cities For The Ultra Rich to Live in Comfort

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!